John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive


Combining biologics in inflammatory bowel disease: Is it useful? Volume 25, issue 10, Décembre 2018


  • Figure 1
  • Figure 2
1 CHU de Nice, Hôpital Archet 2, Service d’hépato-gastroentérologie et de Nutrition clinique, France
2 Tel-Aviv University, Sheba Medical Center, IBD Service, Israel
3 CHU de Saint Etienne, Service d’hépato-gastroentérologie, France
* Tirés à part

The current armamentarium for inflammatory bowel diseases has dramatically evolved those last years, as well as our therapeutic goals. However, many patients still have active diseases, highlighting unmet needs and interest for novel strategies, such as combining biologic therapies.

The aim of this article is to report the current published data regarding the efficacy and safety of the combination of biologics in immune-mediated inflammatory diseases, and particularly in inflammatory bowel diseases.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License